Oral vs Injectable GLP-1 Options: What Should You Know?

For years, many people associated GLP-1 medications primarily with injections. That picture changed significantly in late 2025 and early 2026, when the FDA approved new oral GLP-1 options for chronic weight management. Understanding the differences between oral and injectable GLP-1 medications — including how they are taken, how often, and what the FDA has specifically approved — can help you have a more informed conversation with a healthcare professional.

This article explains the current FDA-approved oral and injectable GLP-1 options, how their administration differs, and what to consider when comparing them. It is educational information, not medical advice. Only a licensed prescriber can determine whether a particular medication is appropriate for you.

Quick Comparison: Oral vs Injectable GLP-1 Options

The Current Landscape

FDA records show Wegovy tablets (oral semaglutide) were originally approved on December 19, 2025, with 25 mg once daily as the adult maintenance dose. FDA-approved labeling requires taking them in the morning on an empty stomach, with no more than 4 ounces of water, and waiting at least 30 minutes before eating food, drinking other beverages, or taking other oral medicines.

On April 1, 2026, the FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist. The FDA specifically states that Foundayo does not need to be taken on an empty stomach — a notable practical difference from Wegovy tablets.

For the injectable comparison, current FDA materials identify Wegovy, Zepbound, and Saxenda among FDA-approved weight-reduction products. Zepbound is administered once weekly; Saxenda is administered once daily; and Wegovy injection is normally administered once weekly. In March 2026, the FDA also approved the 7.2-mg Wegovy HD option, adding a higher-dose injectable semaglutide choice.

These developments mean that as of September 2026, adults considering GLP-1 medications for weight management have both oral and injectable FDA-approved options — each with distinct administration requirements, dosing schedules, and prescribing information.

Oral GLP-1 Options

Wegovy Tablets (Semaglutide)

Wegovy tablets contain semaglutide — the same active ingredient found in Wegovy injections — but in an oral formulation. The FDA originally approved Wegovy tablets on December 19, 2025, for chronic weight management in adults. The adult maintenance dose is 25 mg taken once daily.

Because oral semaglutide has specific absorption requirements, FDA-approved labeling specifies that Wegovy tablets must be taken:

• In the morning
• On an empty stomach
• With no more than 4 ounces of water
• Followed by a wait of at least 30 minutes before food, beverages, or other oral medicines

These instructions are part of the FDA-approved labeling, not optional suggestions. Following them helps the medication absorb properly.

Foundayo (Orforglipron)

Foundayo is the brand name for orforglipron, an oral GLP-1 receptor agonist. The FDA approved it on April 1, 2026, for chronic weight reduction in specified adults. It is taken once daily.

A key practical difference from Wegovy tablets: the FDA specifically states that Foundayo does not need to be taken on an empty stomach. This can simplify the daily routine for some patients, though all dosing decisions are made by the prescribing healthcare professional.

Injectable GLP-1 Options

Wegovy Injection (Semaglutide)

Wegovy injection contains semaglutide and is administered subcutaneously (under the skin). It is normally given once weekly. The March 2026 FDA approval of Wegovy HD at 7.2 mg added a higher-dose option within the injectable semaglutide family.

Zepbound (Tirzepatide)

Zepbound contains tirzepatide and is administered as a subcutaneous injection once weekly. For a detailed comparison of semaglutide and tirzepatide, see our article on Semaglutide vs Tirzepatide.

Saxenda (Liraglutide)

Saxenda contains liraglutide and is administered as a subcutaneous injection once daily. It is one of the earlier FDA-approved injectable GLP-1 options for weight management.

Key Differences: Administration and Convenience

Frequency

• Oral options (Wegovy tablets, Foundayo): once daily
• Wegovy injection: once weekly (normally)
• Zepbound: once weekly
• Saxenda: once daily

Fasting Requirements

• Wegovy tablets: must be taken on an empty stomach with no more than 4 oz water, waiting 30 minutes before food, beverages, or other oral medicines
• Foundayo: does not need to be taken on an empty stomach (per FDA)
• Injectable options: no oral fasting requirement (administered by injection)

Active Ingredients

Oral and injectable GLP-1 products may share active ingredients (e.g., semaglutide is in both Wegovy tablets and Wegovy injection) or use different ones (e.g., orforglipron in Foundayo, tirzepatide in Zepbound, liraglutide in Saxenda). Same active ingredient does not mean same formulation — dosing and administration differ.

Practical Comparison: What Should You Ask?

For guidance on evaluating providers who prescribe these medications, see How to Compare GLP-1 Providers.

What About Products Advertised as "Oral Semaglutide" That Are Not FDA-Approved?

Not every product advertised as "oral semaglutide" is FDA-approved. The FDA has warned that unapproved and compounded GLP-1 products do not undergo FDA premarket review for safety, effectiveness, and quality. Consumers should identify the exact product and use a prescription from a healthcare professional filled through a state-licensed pharmacy.

This is why it matters: an FDA-approved medication like Wegovy tablets has gone through the FDA's review process, with specific labeling on dosing, administration, contraindications, and safety. Products that bypass that process may not meet the same standards.

For more on what to expect after starting with a telehealth provider, see What Happens After Signup?.

Costs and Insurance

GLP-1 medications — oral and injectable — can be expensive, and insurance coverage varies. For a detailed look at coverage factors, see our article on Does Insurance Cover GLP-1 Medications?.

The Bottom Line

As of September 2026, FDA-approved GLP-1 options for weight management include both oral products (Wegovy tablets, Foundayo) and injectable products (Wegovy injection, Wegovy HD, Zepbound, Saxenda). The right choice depends on the active ingredient, formulation, dosing schedule, administration requirements, and — most importantly — what a licensed healthcare professional determines is appropriate for your individual situation.Route alone (oral vs injectable) does not determine safety or effectiveness. Each product has its own prescribing information, and medication decisions should always be directed by a prescribing healthcare professional.

To compare providers who may prescribe these medications, visit our provider comparison page.